Technical Analysis for PBYI - Puma Biotechnology Inc

Grade Last Price % Change Price Change
grade C 25.22 -0.98% -0.25
PBYI closed down 0.98 percent on Friday, January 18, 2019, on 72 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical PBYI trend table...

Date Alert Name Type % Chg
Jan 18 Outside Day Range Expansion 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Stochastic Reached Overbought Strength -0.98%
Jan 17 Wide Bands Range Expansion -0.98%
Jan 17 Overbought Stochastic Strength -0.98%
Jan 17 Up 3 Days in a Row Strength -0.98%
Jan 16 MACD Bullish Centerline Cross Bullish -0.43%
Jan 16 Upper Bollinger Band Touch Strength -0.43%
Jan 15 Crossed Above 50 DMA Bullish 4.17%

Older signals for PBYI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Puma Biotechnology, Inc., a development stage biopharmaceutical company, engages in the acquisition, development, and licensing of products for the treatment of various forms of cancer. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients and non-small cell lung cancer patients; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also involved in developing PB357, an orally administered agent, which is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Is PBYI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 94.85
52 Week Low 17.6
Average Volume 1,064,300
200-Day Moving Average 43.7429
50-Day Moving Average 22.8888
20-Day Moving Average 22.6605
10-Day Moving Average 24.279
Average True Range 1.4963
ADX 27.05
+DI 27.5716
-DI 15.3711
Chandelier Exit (Long, 3 ATRs ) 21.2811
Chandelier Exit (Short, 3 ATRs ) 23.9489
Upper Bollinger Band 26.2379
Lower Bollinger Band 19.0831
Percent B (%b) 0.86
BandWidth 31.573884
MACD Line 0.3445
MACD Signal Line -0.1775
MACD Histogram 0.522
Fundamentals Value
Market Cap 938.32 Million
Num Shares 37.2 Million
EPS -8.14
Price-to-Earnings (P/E) Ratio -3.10
Price-to-Sales 0.00
Price-to-Book 37.58
PEG Ratio 0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 26.89
Resistance 3 (R3) 26.88 26.33 26.61
Resistance 2 (R2) 26.33 25.90 26.33 26.51
Resistance 1 (R1) 25.77 25.64 25.50 25.78 26.42
Pivot Point 25.22 25.22 25.08 25.22 25.22
Support 1 (S1) 24.66 24.79 24.39 24.67 24.02
Support 2 (S2) 24.11 24.53 24.11 23.93
Support 3 (S3) 23.55 24.11 23.83
Support 4 (S4) 23.56